
COYA Stock Forecast & Price Target
COYA Analyst Ratings
Bulls say
Coya Therapeutics is demonstrating progress in its clinical development, evidenced by a significant cognitive stabilization improvement of 4.93 points over placebo in ADAS-Cog scores, highlighting the potential of Treg modulation in Alzheimer's disease. The company's strategic investments and private placements have enhanced its cash position, enabling it to invest in clinical milestones that are anticipated for 2025. Coupled with rising partnerships such as the collaboration with Reddy's, Coya's strengthened financial foundation and commitment to a robust clinical pipeline position it favorably to advance its therapies aimed at neuroinflammation and drive long-term shareholder value.
Bears say
Coya Therapeutics faces significant challenges due to the historical failures associated with ALS drug development, which have been attributed to the disease's heterogeneity and ineffective clinical trial designs. Additionally, the indication that biweekly administration of LD IL-2 may lead to a weaker biological response raises concerns about the potential efficacy of their Treg therapies, further complicating their development strategy. Lastly, while Coya's combination therapy aims to tackle inflammation and immune regulation in ALS, the recent setbacks in the field highlight the risks of relying on a multi-target approach amidst prevalent uncertainties in therapeutic outcomes.
This aggregate rating is based on analysts' research of Coya Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
COYA Analyst Forecast & Price Prediction
Start investing in COYA
Order type
Buy in
Order amount
Est. shares
0 shares